億嘉和(603666.SH)擬與佗道醫療公司的其他股東向其按照同等比例分批繳付認繳的出資額
格隆匯 10 月 21日丨億嘉和(603666.SH)公佈,公司擬與佗道醫療公司的其他股東,即公司關聯方朱付雲、程敏,根據佗道醫療公司未來實際經營的資金需求,以現金方式向佗道醫療公司按照同等比例分批繳付認繳的出資額。公司認繳的出資額共計5100萬元人民幣,朱付雲認繳的出資額共計4800萬元人民幣,程敏認繳的出資額共計100萬元人民幣。
公司控股股東、實際控制人、董事長朱付雲持有佗道醫療公司48%股權,公司監事程敏持有佗道醫療公司1%股權,此次對外投資構成關聯交易。此次對外投資事項未構成重大資產重組。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.